Anti-VEGF drugs and clinical trials

Todd R. Klesert, Jennifer I. Lim, Philip J Rosenfeld

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In 1989, Ferrara and Henzel (1) isolated a diffusible protein from bovine pituitary follicular cells that showed cell-specific mitogenic activity for vascular endothelium. They named this protein vascular endothelial growth factor (VEGF). Further research showed that VEGF was in fact Michelson’s factor X, which was the postulated diffusible angiogenesis factor (2). As discussed in Chapter 5, VEGF was then shown to have a major role in choroidal neovascularization (CNV) (3,4).

Original languageEnglish (US)
Title of host publicationAge-Related Macular Degeneration, Second Edition
PublisherCRC Press
Pages247-256
Number of pages10
ISBN (Electronic)9781420019865
ISBN (Print)9780849372148
StatePublished - Jan 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Anti-VEGF drugs and clinical trials'. Together they form a unique fingerprint.

  • Cite this

    Klesert, T. R., Lim, J. I., & Rosenfeld, P. J. (2007). Anti-VEGF drugs and clinical trials. In Age-Related Macular Degeneration, Second Edition (pp. 247-256). CRC Press.